Vinblastine, rituximab and HAART, treatment of an HIV -positive patient with multicentric Castleman's disease

M C van Aalderen; K Brinkman; G E L van den Berk; W E Terpstra

Vinblastine, rituximab and HAART, treatment of an HIV -positive patient with multicentric Castleman's disease

Neth J Med. 2010 Feb;68(2):87-90.

Authors

M C van Aalderen¹, K Brinkman, G E L van den Berk, W E Terpstra

Affiliation

¹ Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands. [email protected]

PMID: 20167961

Abstract

An HIV-positive man from Somalia presented with severe malaise, weight loss, relapsing fever, lymphadenopathy and splenomegaly. An FDG-PET-scan-guided lymph node biopsy revealed the characteristic histological features of the plasma cell variant of Castleman's disease. A high HHV-8 viral load was detected in the serum (7980 copies/ml). Treatment with HAART, rituximab and vinblastine resulted in a full and rapid recovery and lowered HHV-8 viral load to undetectable levels.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Murine-Derived / therapeutic use*
Antineoplastic Agents, Phytogenic / therapeutic use*
Antiretroviral Therapy, Highly Active*
Castleman Disease / blood
Castleman Disease / drug therapy*
Castleman Disease / virology
HIV Infections / drug therapy*
HIV Infections / virology
Herpesvirus 8, Human / physiology
Humans
Immunologic Factors / therapeutic use
Male
Middle Aged
Prognosis
Rituximab
Vinblastine / therapeutic use*

Substances

Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents, Phytogenic
Immunologic Factors
Rituximab
Vinblastine